GlassScriptPhysician profile
Edgar F Jessee
NPI 1598761447
$2,061.51
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,535 · 2020: $395 · 2021: $110 · 2022: $21.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $343.62 | 2019-2022 | |
| Pfizer INC. | $277.32 | 2019-2020 | |
| Amgen INC. | $275.28 | 2019-2020 | |
| Janssen Biotech, INC. | $191.15 | 2019-2020 | |
| Ucb, INC. | $159.93 | 2019-2020 | |
| Lilly USA, LLC | $151.78 | 2019-2020 | |
| Genentech USA, INC. | $139.91 | 2019-2020 | |
| Celgene Corporation | $98.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $83.19 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $81.55 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.21 | 2019-2020 | |
| Glaxosmithkline, LLC. | $58.64 | 2019 | |
| Mallinckrodt Enterprises LLC | $43.16 | 2019 | |
| Pacira Therapeutics, INC. | $24.95 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $20.09 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $18.36 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.18 | 2019 | |
| Radius Health, INC. | $15.15 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Jessee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.